- Safety Confirmed with No Concerns Reported in Cohort 1 -
- Approval to Immediately Proceed to Cohort 2 -
ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Jun. 13, 2016-- BioTime, Inc. (NYSE MKT and TASE: BTX) and Cell Cure Neurosciences Ltd. (Cell Cure), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell ...
[Continue Reading]
BioTime Subsidiary Cell Cure Neurosciences Announces $2.2 Million Grant for Further Development of Dry-AMD Clinical Program
- Israel Innovation Authority awards a grant to Cell Cure Neurosciences, a BioTime Subsidiary, that will supportongoing development of OpRegen®, to address a leading cause of blindness, dry-AMD
- This is the 10th year in receipt of an Israeli Government grant in support of Cell Cure
ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Jun. 10, ...
[Continue Reading]
BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Receives FDA Fast-Track Designation for OpRegen® for the Treatment of the Dry Form of Age-Related Macular Degeneration
ALAMEDA, CA and JERUSALEM, Israel--Sept. 28, 2015--BioTime, Inc. (NYSE MKT and TASE: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (“Cell Cure”) today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for OpRegen®, a cell-based therapeutic product consisting of retinal pigment epithelial (RPE) ...
[Continue Reading]
Cell Cure Neurosciences Announces Preclinical Efficacy Data Demonstrating OpRegen® Preserves Vision
Data to be Presented at Association for Research in Vision and Ophthalmology (ARVO) 2015 Annual Meeting
ALAMEDA, Calif. and JERUSALEM, Israel, May 4, 2015 – BioTime, Inc. (NYSE MKT and TASE: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced that preclinical data demonstrating that Cell Cure’s product candidate, ...
[Continue Reading]
Cell Cure Neurosciences Ltd. Provides Update on its Product Development and Partnering Activities
ALAMEDA, Calif. & JERUSALEM–(BUSINESS WIRE)–Feb. 17, 2015– BioTime, Inc. (NYSE MKT and TASE: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (“Cell Cure”) today provided an update on Cell Cure’s product development and partnering activities.
On February 16, 2015, Cell Cure opened the clinical trial of OpRegen® titled “Phase I/IIa Dose ...
[Continue Reading]
BioTime’s Subsidiary Cell Cure Neurosciences Receives FDA Authorization to Initiate Phase I/IIa Trial of Embryonic Stem Cell-Derived OpRegen® for the Treatment of the Dry Form of Age-Related Macular Degeneration
• IND cleared for Phase I/IIa dose escalation trial in patients with the dry form of age-related macular degeneration (AMD) called geographic atrophy (GA)
• No approved therapy exists for dry-AMD, the leading cause of visual impairment in an aging population in the US and other developed countries
• OpRegen® will be the first preparation of ...
[Continue Reading]
BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Files an IND with the FDA for OpRegen® Designed to Treat Patients with Dry-AMD
IND filed for a Phase I/IIa dose escalation trial in patients with dry-AMD
No approved therapy exists for dry-AMD, the leading cause of visual impairment in the aging population
OpRegen® will be the first preparation of xeno-free RPE cells to be evaluated clinically for dry-AMD
ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Oct. 6, 2014-- ...
[Continue Reading]
BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Demonstrates the Safety and Efficacy of OpRegen® in Preclinical Animal Studies
ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Sep. 17, 2014-- BioTime, Inc. (NYSE MKT and TASE: BTX), HBL Hadasit Bio-Holdings Ltd. (Tel Aviv Stock Exchange: HDST) and Cell Cure Neurosciences Ltd. (Cell Cure) today announced that Cell Cure has received the final results of a series of extensive preclinical safety and efficacy studies of its ...
[Continue Reading]
BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.7 Million Grant From Israel’s Office of the Chief Scientist
ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Dec. 23, 2013-- BioTime, Inc. (NYSE MKT and TASE: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced that Cell Cure has been awarded a grant for 2014 of 6.1 million Shekels (approximately $1.74 million) from Israel’s Office of the Chief Scientist (OCS) to help finance ...
[Continue Reading]
BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.33 Million Grant From Israel’s Office of the Chief Scientist
ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Aug. 1, 2012-- BioTime, Inc. (NYSE MKT and TASE: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced that Cell Cure has been awarded a grant for 2012 of 5.04 million Shekels (approximately $1.33 million) from Israel’s Office of the Chief Scientist (OCS) to help finance ...
[Continue Reading]